<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04398940</url>
  </required_header>
  <id_info>
    <org_study_id>TQ-B3139-II-02</org_study_id>
    <nct_id>NCT04398940</nct_id>
  </id_info>
  <brief_title>A Study of TQ-B3139 Capsules in Subjects With MET-Altered Advanced Non-small Cell Lung Cancer</brief_title>
  <official_title>A Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of TQ-B3139 in Subjects With MET-Altered Advanced Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-arm, multi-center clinical trial to evaluate the safety and efficacy of
      TQ-B3139 capsules in patients with MET gene abnormal advanced non-small cell lung cancer.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2020</start_date>
  <completion_date type="Anticipated">October 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>up to 18 months</time_frame>
    <description>Percentage of subjects achieving complete response (CR) and partial response (PR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>up to 18 months</time_frame>
    <description>PFS was defined as the time from the date of study enrollment to the date of the first of the following events, objective disease progression or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>up to 18 months</time_frame>
    <description>Percentage of subjects achieving complete response (CR) and partial response (PR) and stable disease (SD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>OS defined as the time from the first dose to death from any cause. Survival time was censored at the date of last contact for patients who were still alive or lost to follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>up to 18 months</time_frame>
    <description>DOR defined as time from earliest date of disease response to earliest date of disease progression based on radiographic assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intracranial progression-free survival (CNS-PFS)</measure>
    <time_frame>up to 18 months</time_frame>
    <description>The time from enrollment to the first confirmed intracranial progression for brain metastases.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intracranial objective response rate (CNS-ORR)</measure>
    <time_frame>up to 18 months</time_frame>
    <description>Percentage of subjects achieving intracranial complete response and partial response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progress of intracranial disease (CNS-TTP)</measure>
    <time_frame>up to 18 months</time_frame>
    <description>The time from the first dose to the first occurrence of intracranial disease progression.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">71</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>TQ-B3139 capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TQ-B3139 capsules administered orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQ-B3139</intervention_name>
    <description>TQ-B3139 capsules administered 600mg orally, twice daily in 28-day cycle.</description>
    <arm_group_label>TQ-B3139 capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1; 2.
             Life expectancy ≥12 weeks; 3. MET-altered non-small cell lung cancer (NSCLC) ; 4. Has
             at least one measurable lesion; 5. Previous standard treatment has failed; 6. Adequate
             organ system function; 7. Left ventricular ejection fraction (LVEF) ≥50%; 8.
             Understood and signed an informed consent form.

        Exclusion Criteria:

          -  1. Has diagnosed and/or treated additional malignancy within 3 years prior to the
             first administration; 2. Has received c-MET inhibitors; 3. Has received other system
             anti-tumor treatment within 4 weeks before the first administration; 4. Has received
             major surgical treatment within 4 weeks before the first administration; 5. Has
             received radiotherapy or any surgery within 2 weeks before the first administration;
             6. Acute toxicity that is ≥ Grade 2 caused by previous cancer therapy; 7. Has active
             infection within 2 weeks before the first administration; 8. Has currently
             uncontrollable congestive heart failure; 9. Has currently uncontrollable congestive
             heart failure; 10. Has continuous arrhythmia ≥ Grade 2, uncontrollable atrial
             fibrillation or QTc interval &gt; 480ms; 11. Has uncontrollable effusion; 12. Has
             interstitial lung diseases; 13. Has severely unstable central nervous system
             metastasis; 14. Has active viral infection; 15. Has multiple factors affecting oral
             medication; 16. Breastfeeding or pregnant women; Men unwilling to use adequate
             contraceptive measures during the study; 17. According to the judgement of the
             researchers, there are other factors that subjects are not suitable for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Baohui Han, Doctor</last_name>
    <phone>021-22200000</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Anhui Provincial Hospital</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yueyin Pan, Doctor</last_name>
      <phone>0551-2283114</phone>
      <email>yueyinpan1965@126.com</email>
    </contact>
    <investigator>
      <last_name>Yueyin Pan, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Sixth Medical Center of PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100010</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Zhihai Han, Doctor</last_name>
      <phone>010-66957581</phone>
      <email>hanzhihai@souhu.com</email>
    </contact>
    <investigator>
      <last_name>Zhihai Han, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Junling Li, Doctor</last_name>
      <phone>010-87788713</phone>
      <email>drlijunling@vip.163.com</email>
    </contact>
    <investigator>
      <last_name>Junling Li, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xuanwu Hospital Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100053</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yi Zhang, Doctor</last_name>
      <phone>010-83192232</phone>
      <email>steven9130@sina.com</email>
    </contact>
    <investigator>
      <last_name>Yi Zhang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Fifth Medical Center of PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100071</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Hong Wang, Doctor</last_name>
      <phone>010－66947163</phone>
    </contact>
    <investigator>
      <last_name>Hong Wang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jian Fang</last_name>
      <phone>010-88196479</phone>
    </contact>
    <investigator>
      <last_name>Jian Fang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guangxi Medical University Affiliated Tumor Hospital</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi Zhuang Autonomous Region</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Qitao Yu</last_name>
      <phone>0771-5328331</phone>
      <email>yqt178@163.com</email>
    </contact>
    <investigator>
      <last_name>Qitao Yu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sir Run Shaw Shaw Hospital, Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Hangzhou</state>
        <zip>310016</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Kejing Ying, Doctor</last_name>
      <phone>0571-86006192</phone>
      <email>yingsrrsh@163.com</email>
    </contact>
    <investigator>
      <last_name>Kejing Ying, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Hangzhou</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Ha'erbin</city>
        <state>Heilongjiang</state>
        <zip>150000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Gongyan Chen, Doctor</last_name>
      <phone>0451-86298265</phone>
      <email>chengongyan@163.com</email>
    </contact>
    <investigator>
      <last_name>Gongyan Chen, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Qiming Wang, Doctor</last_name>
      <phone>400-0371-818</phone>
      <email>qimingwang1006@126.com</email>
    </contact>
    <investigator>
      <last_name>Qiming Wang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangsu Cancer Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Meiqi Shi</last_name>
      <phone>025-83283568</phone>
      <email>shimeiqi1963@163.com</email>
    </contact>
    <investigator>
      <last_name>Meiqi Shi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Chest Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Baohui Han, Doctor</last_name>
      <phone>021-22200000</phone>
    </contact>
    <investigator>
      <last_name>Baohui Han, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jialei Wang</last_name>
      <email>luwangjialei@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Jialei Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University General Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300041</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Diansheng Zhong, Doctor</last_name>
      <phone>022-60817007</phone>
      <email>zhongdsh@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Diansheng Zhong, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>May 19, 2020</study_first_submitted>
  <study_first_submitted_qc>May 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2020</study_first_posted>
  <last_update_submitted>May 19, 2020</last_update_submitted>
  <last_update_submitted_qc>May 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

